ABSTRACT
Background: Cytokine plays a pivotal role in the pathogenesis of coronavirus disease 2019 (COVID-19). Cytokine storm is characterized by rapid elevation of an inflammatory circulating cytokine such as interleukin-6 (IL-6) and IL-1. However, according to evidence, genetic variables may affect the development and course of infectious diseases. Multiple genetic polymorphisms, mostly single-nucleotide polymorphisms (SNPs), have been linked to this setting's predisposition to viral infections. This study aimed to determine the frequency distribution of IL-6 SNPs rs1800795 and IL-1β SNPs rs16944 and rs1143627 gene polymorphisms and their association with the clinical severity of COVID-19 patients in Surakarta, Indonesia. This study aims to determine the association between IL-6 rs1800795 and IL-1β rs16944 with COVID-19 clinical severity. Methods: This study used a cross sectional design conducted at Universitas Sebelas Maret Hospital and centralized isolation of the Donohudan Hajj Dormitory from May to November 2021. A total of 120 COVID-19 patients were divided into 3 groups: asymptomatic, mild-moderate, and severe-critical. The detection of IL-6 SNPs rs1800795 and IL-1β SNPs rs16944 was carried out by quantitative PCR (qPCR) examination, and IL-6 and IL-1β were determined by the ELISA method. Result: There was no significant association between IL-6 SNPs rs1800795 (p=1.000) and IL-1β SNPs rs16944 (p=0.119) with clinical severity. In IL-1β SNPs rs16944 gene polymorphisms, the GG genotype was more commonly found in the asymptomatic group. AG genotype was commonly found in the symptomatic group (mild to critical). There was a significant association between IL-1β levels and clinical severity (p=0.03), whereas the association between IL-6 levels and clinical severity is not significant (p=0.103). Conclusion: There was a correlation between IL-1β levels with clinical severity. In IL-1β SNPs rs16944, the GG genotype may act as a protective factor, whereas the AG genotype may act as a factor that increases the clinical severity of COVID-19. © 2023, Sanglah General Hospital. All rights reserved.
ABSTRACT
Background: Coronavirus Disease 2019 (COVID-19) is an easily contagious disease, and not much is known about the characteristics of COVID-19, both in terms of susceptibility, severity, and spreadability of various SARS-CoV-2 strains. Patient genomic factors, especially related to genomic polymorphisms that affect the body's immune system, can influence the course of infectious diseases. The aim of this study is to get an adequate picture regarding gene polymorphisms, both susceptibility and related to the clinical degree in COVID-19 patients. Methods: The PCR preparations were carried out in the Biomedical laboratory of the Faculty of Medicine, Universitas Sebelas Maret. The qualitative PCR (qPCR) examination was sent to the Genetica Science laboratory, Tangerang, West Java. The research subjects were divided into 3 groups, namely COVID-19 patients with no symptoms, COVID-19 patients with mild-moderate symptoms, COVID-19 patients with severe-critical symptoms. The research subjects were taken 6 cc of venous blood (3 cc for examination of serum IL-6 and TNFα levels and 3 cc for DNA examination). Results: Serum levels of IL-6 and TNF-α in the clinical grade group were almost all above normal values. The frequency of TNF-α polymorphisms (-376G/A) all showed homozygote GG. TNF-α (-308G/A) also showed homozygote GG was dominant for SARS CoV2. IL-6 (-572G/C) polymorphism for cases requiring medium and severe clinical degree hospitalization was found to have more C allele than G allele. IL-6 polymorphism (intron A/G) the G allele is less common in cases requiring hospitalization. Conclusion: TNF-α(−308A) allele has an influence on the development of clinical symptoms of SARS CoV2 infection. The rs1800796GG genotype in the IL-6 promoter contributes to milder symptoms in SARS CoV2 infection. Allelic variants of the gene under study may show different effects in other races depending on their interactions with other risk factors. © 2022, Sanglah General Hospital. All rights reserved.
ABSTRACT
Background: Coronavirus Disease 2019 (COVID-19) is an easily contagious disease, and not much is known about the characteristics of COVID-19, both in terms of susceptibility, severity, and spreadability of various SARS-CoV-2 strains. Patient genomic factors, especially related to genomic polymorphisms that affect the body's immune system, can influence the course of infectious diseases. The aim of this study is to get an adequate picture regarding gene polymorphisms, both susceptibility and related to the clinical degree in COVID-19 patients.Methods: The PCR preparations were carried out in the Biomedical laboratory of the Faculty of Medicine, Universitas Sebelas Maret. The qualitative PCR (qPCR) examination was sent to the Genetica Science laboratory, Tangerang, West Java. The research subjects were divided into 3 groups, namely COVID-19 patients with no symptoms, COVID-19 patients with mild -moderate symptoms, COVID-19 patients with severe-critical symptoms. The research subjects were taken 6 cc of venous blood (3 cc for examination of serum IL-6 and TNF alpha levels and 3 cc for DNA examination).Results: Serum levels of IL-6 and TNF-alpha in the clinical grade group were almost all above normal values. The frequency of TNF-alpha polymorphisms (-376G/A) all showed homozygote GG. TNF-alpha (-308G/A) also showed homozygote GG was dominant for SARS CoV2. IL-6 (-572G/C) polymorphism for cases requiring medium and severe clinical degree hospitalization was found to have more C allele than G allele. IL-6 polymorphism (intron A/G) the G allele is less common in cases requiring hospitalization.Conclusion: TNF-alpha(-308A) allele has an influence on the development of clinical symptoms of SARS CoV2 infection. The rs1800796GG genotype in the IL-6 promoter contributes to milder symptoms in SARS CoV2 infection. Allelic variants of the gene under study may show different effects in other races depending on their interactions with other risk factors.
ABSTRACT
Introduction: To date, no specific therapeutic drug has been approved to target SARS-CoV-2. Hence, it remains a major challenge to decide what potential therapeutic regimens to treat COVID-19 patients. This study aims to investigate curcumin and virgin coconut oil (VCO) effects on cytokine levels (IL-1β, IL-2, IL-6, IL-18, TNF-α, and IFN-β) in COVID-19 patients. Methods: This study was a single-center, controlled trial with a parallel Arm or a Randomized Clinical trial design. A total of sixty COVID-19 patients admitted to the Universitas Sebelas Maret Hospital, Surakarta, Indonesia, were divided into two groups. The first group, consisting of 30 patients, was treated with Azithromycin 500 mg + Oseltamivir 2×75 mg + Hydroxychloroquine 400 mg/day for 5 days. The second group, comprising 30 patients, was treated with Azithromycin 500 mg + Oseltamivir 2×75 mg + Hydroxychloroquine 400 mg/day for 5 days, added with VCO 30 mL and curcumin 3×1 g/day for 21 days. The cytokine profiles of the serum samples were analyzed by the enzyme-linked immunosorbent assay (ELISA) on days 1, 14, and 21. Results: Our study showed that the second group had a significant reduction in IL-1β, IL-2, IL-6, TNF-α, and IFN-β levels after being treated with standard therapy added with curcumin and VCO on day 21 (p<0.05). Conclusion: These results su ested that curcumin and VCO mi ht benefit the treatment of COVID-19 atients
ABSTRACT
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is now causing a pandemic with a rapid spread and become a global public health problem. Coronavirus illness-2019 is a potentially lethal disease, especially for patients with comorbidities. Natural killer (NK) cells are important in controlling the immunological response in COVID-19 patients, but their effector capabilities are disturbed in those with comorbidities. Preliminary research in COVID-19 patients with severe illness reveals a drop in NK cells quantity and activity, leading to a decrease in the clearance of infected and activated cells and an unregulated rise in tissue-damaging inflammatory markers. Knowing the mechanism and role of NK cells in COVID-19 becomes necessary for better understanding and treatment of COVID-19. © 2021 Teikyo University School of Medicine. All rights reserved.